This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
3 Stocks Worth a Buy for Superb Earnings Acceleration
by Tirthankar Chakraborty
Invest in stocks such as Freshpet (FRPT), OptimizeRx (OPRX) and Pinterest (PINS) at the moment for solid earnings acceleration.
Why OptimizeRx Corp. (OPRX) Might be Well Poised for a Surge
by Zacks Equity Research
OptimizeRx Corp. (OPRX) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
How Much Upside is Left in OptimizeRx Corp. (OPRX)? Wall Street Analysts Think 47.72%
by Zacks Equity Research
The mean of analysts' price targets for OptimizeRx Corp. (OPRX) points to a 47.7% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
OptimizeRx Corp. (OPRX) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
by Zacks Equity Research
OptimizeRx Corp. (OPRX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
OptimizeRx Corp. (OPRX) Surges 13.0%: Is This an Indication of Further Gains?
by Zacks Equity Research
OptimizeRx Corp. (OPRX) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
OptimizeRx Corp. (OPRX) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
OptimizeRx Corp. (OPRX) delivered earnings and revenue surprises of -12.50% and 5.10%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
OptimizeRx Corp. (OPRX) Soars 7.2%: Is Further Upside Left in the Stock?
by Zacks Equity Research
OptimizeRx Corp. (OPRX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
OptimizeRx Corp. (OPRX) Q4 Earnings Beat Estimates
by Zacks Equity Research
OptimizeRx Corp. (OPRX) delivered earnings and revenue surprises of 4.17% and 9.81%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Sea Limited (SE) to Report Q4 Earnings: What's in Store?
by Zacks Equity Research
Sea Limited's (SE) fourth-quarter 2022 results are likely to benefit from a stable Free Fire user base and the growing popularity of Shopee.
VMware (VMW) Q4 Earnings and Revenues Top Estimates
by Zacks Equity Research
VMware (VMW) delivered earnings and revenue surprises of 7.58% and 2.16%, respectively, for the quarter ended January 2023. Do the numbers hold clues to what lies ahead for the stock?
Should You Buy OptimizeRx (OPRX) Ahead of Earnings?
by Zacks Equity Research
OptimizeRx (OPRX) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Oracle (ORCL) Earnings Expected to Grow: Should You Buy?
by Zacks Equity Research
Oracle (ORCL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Avid Technology (AVID) Q4 Earnings Lag Estimates
by Zacks Equity Research
Avid (AVID) delivered earnings and revenue surprises of -4.26% and 1.76%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
OptimizeRx Corp. (OPRX) to Report Q4 Results: Wall Street Expects Earnings Growth
by Zacks Equity Research
OptimizeRx Corp. (OPRX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Strength Seen in OptimizeRx Corp. (OPRX): Can Its 10.1% Jump Turn into More Strength?
by Zacks Equity Research
OptimizeRx Corp. (OPRX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
OptimizeRx Corp. (OPRX) Tops Q3 Earnings Estimates
by Zacks Equity Research
OptimizeRx Corp. (OPRX) delivered earnings and revenue surprises of 75% and 0.47%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Commvault Systems (CVLT) Q2 Earnings and Revenues Top Estimates
by Zacks Equity Research
Commvault (CVLT) delivered earnings and revenue surprises of 14% and 0.82%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
OptimizeRx Corp. (OPRX) Misses Q2 Earnings and Revenue Estimates
by Zacks Equity Research
OptimizeRx Corp. (OPRX) delivered earnings and revenue surprises of -60% and 18.26%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
OptimizeRx Corp. (OPRX) Reports Next Week: What to Know Ahead of the Release
by Zacks Equity Research
OptimizeRx Corp. (OPRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
PTC Inc. (PTC) Misses Q3 Earnings and Revenue Estimates
by Zacks Equity Research
PTC Inc. (PTC) delivered earnings and revenue surprises of -9.35% and 2.80%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Manhattan Associates (MANH) Q2 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Manhattan Associates (MANH) delivered earnings and revenue surprises of 30.19% and 6.71%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
OptimizeRx Corp. (OPRX) Moves 8.9% Higher: Will This Strength Last?
by Zacks Equity Research
OptimizeRx Corp. (OPRX) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
OptimizeRx Corp. (OPRX) Reports Q1 Loss, Lags Revenue Estimates
by Zacks Equity Research
OptimizeRx Corp. (OPRX) delivered earnings and revenue surprises of -200% and 0.36%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Sapiens (SPNS) Beats Q1 Earnings and Revenue Estimates
by Zacks Equity Research
Sapiens (SPNS) delivered earnings and revenue surprises of 14.81% and 0.39%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Earnings Preview: OptimizeRx Corp. (OPRX) Q1 Earnings Expected to Decline
by Zacks Equity Research
OptimizeRx Corp. (OPRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.